VSTM - Verastem Inc
IEX Last Trade
2.5
0.040 1.600%
Share volume: 369,061
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.46
0.04
1.63%
Fundamental analysis
23%
Profitability
25%
Dept financing
14%
Liquidity
75%
Performance
10%
Performance
5 Days
1.63%
1 Month
-6.37%
3 Months
-37.34%
6 Months
-80.48%
1 Year
-74.95%
2 Year
-82.34%
Key data
Stock price
$2.50
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.10 - $14.22
52 WEEK CHANGE
-$0.75
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Brian Stuglik
Region: US
Website: http://www.verastem.com/
Employees: 74
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.verastem.com/
Employees: 74
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Recent news